Associations of VEGF/VEGF-Receptor and HGF/c-Met Promoter Polymorphisms With Progression/Regression of Retinopathy of Prematurity

REFERENCES

• Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628–1640.
   PubMed Web of Science ®Google Scholar
• Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkerson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003;163:879–887.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Awan H. Blindness in children. BMJ 2003;327:760–761.
   PubMed Web of Science ®Google Scholar
• Holmström G, el Azazi M, Jacobson L, Lennerstrand G. A population based, prospective study of the development of ROP in prematurely born children in the Stockholm area of Sweden. Br J Ophthalmol 1993;77:417–423.
   Google Scholar
• Larsson E, Carle-Petrelius B, Cernerud G, Ots L, Wallin A, Holmström G. Incidence of ROP in two consecutive Swedish population based studies. Br J Ophthalmol 2002;86:1122–1126.
   PubMed Web of Science ®Google Scholar
• Holmström G, van Wijngaarden P, Coster DJ, Williams KA. Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br J Ophthalmol 2007;91:1704–1708.
   Google Scholar
• Avery GB, Glass P. Retinopathy of prematurity: progress report. Pediatr Ann 1988;17:520, 530, 532–3.
   Google Scholar
• Kim TI, Sohn J, Pi SY, Yoon YH. Postnatal risk factors of retinopathy of prematurity. Paediatr Perinat Epidemiol 2004;18:130–134.
   PubMed Web of Science ®Google Scholar
• Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. a multivariate statistical analysis. Ophthalmologica 2000;214:131–135.
   PubMed Web of Science ®Google Scholar
• Brown BA, Thach AB, Song JC, Marx JL, Kwun RC, Frambach DA. Retinopathy of prematurity: evaluation of risk factors. Int Ophthalmol 1998;22:279–283.
   Google Scholar
• Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003;8:469–473.
   PubMedGoogle Scholar
• Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith BT. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol 2006;141:167–174.
   Google Scholar
• Mechoulam H, Pierce EA. Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am J Pharmacogenomics 2003;3:261–277.
   PubMedGoogle Scholar
• Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol 2002;86:696–700.
   Google Scholar
• Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP). J Biomed Sci 2010;17:69.
   PubMed Web of Science ®Google Scholar
• Hutcheson KA, Paluru PC, Bernstein SL, Koh J, Rappaport EF, Leach RA et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol Vis 2005;11:501–508.
   PubMed Web of Science ®Google Scholar
• Floyd BN, Leske DA, Wren SM, Mookadam M, Fautsch MP, Holmes JM. Differences between rat strains in models of retinopathy of prematurity. Mol Vis 2005;11:524–530.
   PubMed Web of Science ®Google Scholar
• Csak K, Szabo V, Szabo A, Vannay A. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci 2006;11:908–920.
   PubMed Web of Science ®Google Scholar
• Cooke RW, Drury JA, Mountford R et al. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci 2004;45:1712–1715.
   PubMed Web of Science ®Google Scholar
• Vannay A, Dunai G, Bányász I, Szabó M, Vámos R, Treszl A et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 2005;57:396–398.
   PubMed Web of Science ®Google Scholar
• Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1467–1475.
   PubMed Web of Science ®Google Scholar
• Shastry BS, Qu X. Lack of association of the VEGF gene promoter (-634 G–>C and -460 C–>T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:741–743.
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835–846.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915–925.
   PubMed Web of Science ®Google Scholar
• Rosário M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003;13:328–335.
   PubMed Web of Science ®Google Scholar
• Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003;140:595–610.
   PubMed Web of Science ®Google Scholar
• Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337–1344.
   PubMed Web of Science ®Google Scholar
• Kimura K, Teranishi S, Kawamoto K, Nishida T. Protection of human corneal epithelial cells from hypoxia-induced disruption of barrier function by hepatocyte growth factor. Exp Eye Res 2010;90:337–343.
   Google Scholar
• Early Treatment for Retinopathy of Prematurity Cooperative Group. Results of the early treatment for retinopathy of prematurity randomized trial: revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol 2003;121:1684–1696.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P et al.; International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115:e518–e525.
   PubMed Web of Science ®Google Scholar
• Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL et al. Low IGF-1 suppresses VEGF survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001;98:5804–5808.
   PubMed Web of Science ®Google Scholar
• Fang AM, Lee AY, Kulkarni M, Osborn MP, Brantley MA Jr. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis 2009;15:2710–2719.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203–212.
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–66.
   PubMed Web of Science ®Google Scholar
• Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005;10:382–391.
   PubMed Web of Science ®Google Scholar
• Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009;115:1701–1712.
   PubMed Web of Science ®Google Scholar
• Pabst S, Karpushova A, Diaz-Lacava A, Herms S, Walier M, Zimmer S et al. VEGF gene haplotypes are associated with sarcoidosis. Chest 2010;137:156–163.
   Google Scholar
• Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007;50:760–767.
   PubMed Web of Science ®Google Scholar
• Försti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K et al. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat 2007;101:83–93.
   Google Scholar
• Grant DS, Kleinman HK, Goldberg ID, Bhargaya MM, Nickoloff BJ, Kinsella JL et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937–1941.
   PubMed Web of Science ®Google Scholar
• Rosen EM, Zitnik RJ, Elias JA, Bhargava MM, Wines J, Goldberg ID. The interaction of HGF-SF with other cytokines in tumor invasion and angiogenesis. EXS 1993;65:301–310.
   Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718–12723.
   PubMed Web of Science ®Google Scholar
• Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999;79:427–438.
   PubMed Web of Science ®Google Scholar
• Colombo ES, Menicucci G, McGuire PG, Das A. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci 2007;48:1793–1800.
   PubMed Web of Science ®Google Scholar